ADVFN Logo
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

ARGX Argen X SE

424,00
-0,50 (-0,12%)
08 Déc 2023 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Argen X SE ARGX Euronext Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
-0,50 -0,12% 424,00 17:40:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
424,00 423,30 431,00 424,00 424,50
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
28/11/202307:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
16/11/202313:40GLOBEargenx Announces European Commission Approval of..
01/11/202307:00GLOBEargenx to Present at Upcoming Investor Conferences
31/10/202307:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
24/10/202307:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
21/9/202307:00GLOBEargenx Announces VYVGART (efgartigimod alfa) Authorized for..
15/9/202307:00GLOBEargenx Announces Positive CHMP Opinion for Subcutaneous..
30/8/202307:00GLOBEargenx to Present at Upcoming Investor Conferences
27/7/202307:00GLOBEargenx Reports Half Year 2023 Financial Results and Provides..
24/7/202322:30GLOBEargenx announces closing of global offering
20/7/202307:00GLOBEargenx to Report Half Year 2023 Financial Results and Second..
19/7/202323:58GLOBEargenx announces full exercise of underwriters’ option to..
19/7/202303:30GLOBEargenx raises $1.1 billion in gross proceeds in a global..
17/7/202322:01GLOBEargenx announces launch of proposed global offering
17/7/202307:00GLOBEargenx Reports Positive Topline Data from ADHERE Study of..
30/6/202315:39GLOBEargenx and Zai Lab Announce Approval of VYVGART®..
21/6/202300:12GLOBEargenx Announces U.S. Food and Drug Administration Approval..
20/6/202307:00GLOBEargenx Initiates Second Cohort of Phase 2 ARDA Study of..
31/5/202307:00GLOBEargenx to Present at Upcoming Investor Conferences
04/5/202307:00GLOBEargenx Reports First Quarter 2023 Financial Results and..
03/5/202322:01GLOBEargenx announces results of Annual General Meeting of..
02/5/202307:00GLOBEargenx to Present at BofA Securities 2023 Health Care..
27/4/202307:00GLOBEargenx to Report First Quarter 2023 Financial Results and..
18/4/202307:00GLOBEargenx Demonstrates Commitment to Redefining Treatment Goals..
17/4/202308:00GLOBEargenx and Genmab Enter Partnership to Advance Antibody..
17/3/202321:01GLOBEargenx Announces Annual General Meeting of Shareholders on..
15/3/202314:25GLOBEargenx Announces UK MHRA Approval of VYVGART for the..
02/3/202307:00GLOBEargenx Reports Full Year 2022 Financial Results and Provides..
27/2/202322:01GLOBEargenx Appoints Steve Krognes to Board of Directors
27/2/202307:00GLOBEargenx to Present at Upcoming Investor Conferences
23/2/202307:00GLOBEargenx to Report Full Year 2022 Financial Results and Fourth..
27/1/202307:00GLOBEargenx Receives Notification of PDUFA Date Extension for SC..
16/1/202319:30GLOBEargenx Announces Extraordinary General Meeting of..
09/1/202307:00GLOBEargenx Highlights 2023 Strategic Priorities Across..
03/1/202307:00GLOBEargenx to Present at 41st Annual J.P. Morgan Healthcare..
12/12/202222:01GLOBEargenx Appoints Ana Cespedes to Board of Directors
10/12/202217:30GLOBEargenx to Present Pivotal ADVANCE Trial Data During ASH..

Dernières Valeurs Consultées

Delayed Upgrade Clock

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

Support: support@advfn.fr